Profile data is unavailable for this security.
About the company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
- Revenue in USD (TTM)411.33m
- Net income in USD271.17m
- Incorporated1996
- Employees159.00
- LocationInnoviva Inc1350 OLD BAYSHORE HIGHWAY, SUITE 400BURLINGAME 94010United StatesUSA
- Phone+1 (650) 238-9600
- Fax+1 (302) 655-5049
- Websitehttps://www.inva.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Inc | 31.37m | -231.96m | 1.31bn | 214.00 | -- | 4.26 | -- | 41.89 | -3.16 | -3.16 | 0.4283 | 3.70 | 0.0802 | 1.00 | 49.88 | 146,598.10 | -59.29 | -41.12 | -66.62 | -47.59 | 93.41 | 86.48 | -739.39 | -298.63 | 8.83 | -- | 0.00 | -- | -27.50 | -1.85 | -77.25 | -- | 55.39 | -- |
| Harrow Inc | 272.30m | -5.14m | 1.35bn | 373.00 | -- | 25.80 | 98.19 | 4.97 | -0.1637 | -0.1637 | 7.22 | 1.41 | 0.6907 | 5.61 | 2.40 | 730,034.90 | -1.30 | -6.68 | -1.71 | -8.20 | 75.05 | 73.74 | -1.89 | -10.37 | 2.06 | 1.26 | 0.8236 | -- | 36.41 | 40.99 | 70.60 | -- | 5.04 | -- |
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.48bn | 8.10k | -- | 0.5025 | -- | 0.347 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Innoviva Inc | 411.33m | 271.17m | 1.63bn | 159.00 | 7.12 | 1.40 | 5.24 | 3.97 | 3.10 | 3.10 | 5.18 | 15.71 | 0.2802 | 2.84 | 4.58 | 2,586,969.00 | 18.47 | 17.66 | 20.46 | 19.58 | 74.80 | -- | 65.92 | 58.96 | 13.85 | -- | 0.1802 | -- | 14.67 | 4.08 | 1,059.22 | 3.86 | 281.45 | -- |
| Harmony Biosciences Holdings Inc | 868.45m | 158.69m | 1.64bn | 293.00 | 10.44 | 1.88 | 8.90 | 1.89 | 2.71 | 2.71 | 14.87 | 15.07 | 0.7649 | 31.60 | 9.66 | 2,964,004.00 | 13.98 | 17.23 | 17.21 | 20.92 | 77.16 | 78.84 | 18.27 | 22.32 | 3.58 | -- | 0.1583 | -- | 21.51 | 40.30 | 9.07 | -- | 528.16 | -- |
| ANI Pharmaceuticals Inc | 883.37m | 70.21m | 1.66bn | 970.00 | 22.23 | 3.08 | 9.85 | 1.88 | 3.33 | 3.33 | 42.25 | 24.03 | 0.6484 | 2.44 | 3.51 | 910,686.60 | 5.75 | -0.2549 | 6.96 | -0.3002 | 61.36 | 59.78 | 8.87 | -0.473 | 2.19 | 6.58 | 0.533 | -- | 43.78 | 33.48 | 448.52 | -- | 17.66 | -- |
| Immunocore Holdings PLC - ADR | 400.02m | -35.51m | 1.67bn | 524.00 | -- | 4.38 | -- | 4.17 | -0.7057 | -0.7057 | 7.87 | 7.52 | 0.3852 | 0.8348 | 5.84 | 763,389.30 | -3.42 | -11.69 | -4.39 | -14.93 | 98.73 | -- | -8.88 | -32.06 | 4.01 | -- | 0.5078 | -- | 28.95 | 59.62 | 30.48 | -- | 1.95 | -- |
| Organon & Co | 6.22bn | 187.00m | 1.71bn | 10.00k | 9.15 | 2.27 | 3.12 | 0.2747 | 0.7166 | 0.7166 | 23.86 | 2.89 | 0.4787 | 2.13 | 4.62 | 621,600.00 | 1.44 | 7.45 | 1.79 | 9.65 | 53.30 | 59.42 | 3.01 | 13.85 | 1.23 | 2.62 | 0.92 | 25.68 | -2.92 | -0.9868 | -78.36 | -39.23 | 4.38 | -- |
| Vericel Corp | 276.26m | 16.52m | 1.71bn | 398.00 | 128.03 | 4.81 | 60.67 | 6.19 | 0.2633 | 0.2633 | 5.26 | 7.01 | 0.6001 | 4.05 | 3.78 | 694,118.10 | 3.59 | -0.0292 | 4.02 | -0.0331 | 74.42 | 70.68 | 5.98 | -0.0467 | 4.68 | -- | 0.0056 | -- | 16.45 | 17.34 | 59.41 | 41.97 | 59.56 | -- |
| Sarepta Therapeutics Inc | 2.20bn | -713.41m | 1.75bn | 835.00 | -- | 1.54 | -- | 0.7981 | -7.20 | -7.20 | 21.50 | 10.87 | 0.6012 | 0.8101 | 4.40 | 2,632,619.00 | -19.51 | -12.81 | -26.01 | -15.87 | 69.33 | 80.21 | -32.45 | -30.61 | 1.48 | -21.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | 5.09 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.81bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Aurinia Pharmaceuticals Inc | 283.06m | 287.20m | 1.90bn | 300.00 | 6.89 | 3.26 | 6.21 | 6.73 | 2.08 | 2.08 | 2.04 | 4.39 | 0.4347 | 0.7693 | 7.26 | -- | 44.11 | -2.73 | 51.71 | -3.10 | 88.46 | 90.63 | 101.47 | -8.50 | 4.76 | -- | 0.1059 | -- | 20.38 | 41.38 | 4,893.08 | -- | -49.05 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 1.94bn | 2.48k | 21.25 | 5.84 | 13.60 | 1.33 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Ultragenyx Pharmaceutical Inc | 673.00m | -575.00m | 2.05bn | 1.37k | -- | -- | -- | 3.05 | -5.83 | -5.83 | 6.83 | -0.8282 | 0.4434 | 2.25 | 4.81 | 490,882.60 | -37.89 | -37.78 | -50.15 | -45.91 | 83.80 | 88.44 | -85.44 | -122.25 | 2.34 | -14.66 | 1.07 | -- | 20.13 | 19.95 | -1.02 | -- | -13.71 | -- |
Data as of Mar 06 2026. Currency figures normalised to Innoviva Inc's reporting currency: US Dollar USD
52.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 9.46m | 12.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.34m | 9.82% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 4.21m | 5.63% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 4.18m | 5.60% |
| Sarissa Capital Management LPas of 31 Dec 2025 | 2.82m | 3.77% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.80m | 3.74% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 2.36m | 3.15% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 2.24m | 3.00% |
| Systematic Financial Management LPas of 31 Dec 2025 | 2.11m | 2.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.75m | 2.34% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
